2024 CEO Chat: Eric Shaff, CEO of Seres Therapeutics

preview_player
Показать описание
Seres Therapeutics CEO Eric Shaff on the patient impact of VOSWT, the first ever approved oral microbiome drug for recurrent C.diff, and why this is only the beginning for the microbiome as a new field of medicine.

About Flagship Pioneering:
Flagship Pioneering is a biotechnology company that invents and builds platform companies, each with the potential for multiple products that transform human health or sustainability. Since its launch in 2000, Flagship has originated and fostered more than 100 scientific ventures. The current Flagship ecosystem comprises 40 companies, including Denali Therapeutics, Foghorn Therapeutics, Generate:Biomedicines, Inari, Indigo Agriculture, Moderna , Omega Therapeutics, Sana Biotechnology, Seres Therapeutics, and Tessera Therapeutics.

Twitter: @FlagshipPioneer
Рекомендации по теме
Комментарии
Автор

Super elegant, decent, and quick. Investors have to acknowledge that traditional medicine has to keep some skepticism toward all new endeavors. And that the only way to quantify it's effect is through thoroughly painfully slow human trials. And finally the strictness and adherence to science will only solidify but make the progress long term. With few spikes here and there.

henrikarboejensen
Автор

Great things going to come. At the current share price it is a true bargain.

Ryjax-biqd
Автор

Nice chat Eric. How about your shareholders? How about the share price getting totally destroyed, $1.25/sh this afternoon. Yesterday they traded over $2 for a brief moment... It would appear the only path forward to repair the share price to say at least $5 is to sell the company to Nestle and fire the entire management, including you. I don't see you or your team capable or competent going forward. Goldman Sachs downgraded the company down to $1.25 back in Nov/2023. It would appear they were correct, Seres is nothing more than penny status. Sad.

rondegroot